Processa (NASDAQ: PCSA) CEO George Ng buys 2,034 shares in open-market trade

Q: How many Processa Pharmaceuticals (PCSA) shares does George Ng own directly after this filing?

After the reported transaction, George K. Ng holds 6,013 shares of Processa Pharmaceuticals Common Stock directly. This figure reflects his direct ownership following the open-market purchase of 2,034 shares at $2.69 per share on April 30, 2026 .

Q: What indirect PCSA shareholdings are reported for George Ng on this Form 4?

The filing shows indirect ownership of 800 shares held by the Ng Cha Family Trust and 3,488 shares held under " George Ng IRRA FOB George Ng ." These entries are reported as indirect Common Stock holdings as of April 30, 2026 .

Q: Is the insider activity on this PCSA Form 4 primarily buying or selling?

The activity is primarily buying . The transaction summary shows one buy totaling 2,034 shares and no reported sales. Additional entries are holdings records with unknown codes, but no dispositions or sales are disclosed in this Form 4.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. director and Chief Executive Officer George K. Ng reported an open-market purchase of 2,034 shares of Common Stock at $2.69 per share. This buy increased his direct ownership to 6,013 shares of Common Stock.

As of the transaction date, he also reported indirect ownership of 800 shares held by the Ng Cha Family Trust and 3,488 shares held under "George Ng IRRA FOB George Ng." All holdings reflect positions as of April 30, 2026.

Insider Trade Summary

Net Buyer: 2,034 shares ($5,471)

Net Buy 3 txns

Insider Ng George K

Role Chief Executive Officer

Bought 2,034 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,034	$2.69	$5K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 6,013 shares (Direct, null); Common Stock — 3,488 shares (Indirect, George Ng IRRA FOB George Ng)

Footnotes (1)

Key Figures

Open-market purchase: 2,034 shares Purchase price: $2.69 per share Direct holdings after transaction: 6,013 shares +3 more

6 metrics

Open-market purchase 2,034 shares Common Stock bought on April 30, 2026

Purchase price $2.69 per share Price for Common Stock on April 30, 2026

Direct holdings after transaction 6,013 shares Common Stock directly owned after April 30, 2026 trade

Indirect holdings - Ng Cha Family Trust 800 shares Common Stock held indirectly as of April 30, 2026

Indirect holdings - IRRA account 3,488 shares Common Stock held under "George Ng IRRA FOB George Ng"

Net buy shares 2,034 shares Net buying activity in transaction summary

Key Terms

Common Stock, open-market purchase, indirect, transaction code

4 terms

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open-market purchase financial

"transaction_action: "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect financial

"ownership_type: "indirect""

transaction code financial

"transaction_code_description: "Unknown transaction code""

Form 4 Insider Transactions: What Each Field Means →

05/01/2026 - 04:37 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ng George K

(Last)

(First)

(Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH

FLORIDA

32960

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/30/2026		P		2,034	A	$2.69	6,013	D
Common Stock								3,488	I	George Ng IRRA FOB George Ng
Common Stock								800	I	Ng Cha Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	/s/ George Ng, by John J. Wolfel, as Attorney-in-Fact	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did PCSA CEO George Ng report on this Form 4?

George K. Ng, CEO of Processa Pharmaceuticals (PCSA), reported an open-market purchase of 2,034 shares of Common Stock at $2.69 per share. This transaction represents a direct increase in his personal share ownership disclosed for April 30, 2026.

How many Processa Pharmaceuticals (PCSA) shares does George Ng own directly after this filing?

After the reported transaction, George K. Ng holds 6,013 shares of Processa Pharmaceuticals Common Stock directly. This figure reflects his direct ownership following the open-market purchase of 2,034 shares at $2.69 per share on April 30, 2026.

What indirect PCSA shareholdings are reported for George Ng on this Form 4?

The filing shows indirect ownership of 800 shares held by the Ng Cha Family Trust and 3,488 shares held under "George Ng IRRA FOB George Ng." These entries are reported as indirect Common Stock holdings as of April 30, 2026.

What does the transaction code on George Ng’s PCSA Form 4 indicate?

The Form 4 lists transaction code P for the main entry, described as a purchase in open market or private transaction. This means the 2,034 PCSA Common Stock shares were acquired through an open-market purchase rather than a grant, award, or option exercise.

Is the insider activity on this PCSA Form 4 primarily buying or selling?

The activity is primarily buying. The transaction summary shows one buy totaling 2,034 shares and no reported sales. Additional entries are holdings records with unknown codes, but no dispositions or sales are disclosed in this Form 4.